Hayato Koba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hayato Koba has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Kazuo Kasahara
Department of Pulmonary Medicine and Oncology Graduate School of Medicine, Nippon Medical School Tokyo Japan
6 shared publicationsNanao Terada
Department of Respiratory Medicine, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan
6 shared publicationsSeiji Yano
Kanazawa University Graduate School of Medical Sciences
6 shared publications- Taro Yoneda
Komatsu Municipal Hospital
6 shared publications Tsukasa Ueda
Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Japan
6 shared publications- Yuichi Tambo
Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Japan
6 shared publications
Latest Publications
- 1 November 2026
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 331 (5) , L487-L502
Neutrophils and CSF1 promote the expansion of monocyte-derived alveolar macrophages in progressive pulmonary fibrosis
We show that neutrophils and colony-stimulating factor 1 (CSF1) signaling promote the expansion of monocyte-derived alveolar macrophages in progressive pulmonary fibrosis. We identify a distinct Csf1-expressing neutrophil subpopulation in a progressive pulmonary fibrosis model, suggesting that neutrophil-derived CSF1 may represent one potential mechanism contributing to macrophage expansion. These findings provide new mechanistic insight into how persistent macrophage accumulation contributes to progressive fibrotic remodeling.
- 1 November 2026
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 331 (5) , L487-L502
Neutrophils and CSF1 promote the expansion of monocyte-derived alveolar macrophages in progressive pulmonary fibrosis
We show that neutrophils and colony-stimulating factor 1 (CSF1) signaling promote the expansion of monocyte-derived alveolar macrophages in progressive pulmonary fibrosis. We identify a distinct Csf1-expressing neutrophil subpopulation in a progressive pulmonary fibrosis model, suggesting that neutrophil-derived CSF1 may represent one potential mechanism contributing to macrophage expansion. These findings provide new mechanistic insight into how persistent macrophage accumulation contributes to progressive fibrotic remodeling.
- Open Access
- 9 June 2026
- Published by Elsevier in Lung Cancer
- Vol. 218, 109492
Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report
- 9 June 2026
- Published by Elsevier in Lung Cancer
- Vol. 218, 109492
Open AccessRechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report
- Open Access
- 4 November 2025
- Published by Elsevier in Lung Cancer
- Vol. 213, 108818
Prognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancer
- 4 November 2025
- Published by Elsevier in Lung Cancer
- Vol. 213, 108818
Open AccessPrognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancer
- Open Access
- 22 August 2025
- Published by Wiley in The Journal of Pathology
- Vol. 267 (2) , 168-180
Characteristic miRNA profiles represent clinicopathological diversity of small cell lung cancer
Small cell lung cancer (SCLC) is classified into distinct molecular subtypes based on the expression patterns of four transcription regulators: achaete–scute homolog 1 (ASCL1), neuronal differentiation 1 (NEUROD1), POU class 2 homeobox 3 (POU2F3), and yes‐associated protein 1 (YAP1). MicroRNAs (miRNAs) play critical roles in cancer cellular processes but their subtype‐specific implications in SCLC remain underexplored. Out of 46 surgically resected SCLC samples, miRNA visualization through in situ hybridization identified high expression of miR‐375 in the ASCL1, NEUROD1, and ASCL1/NEUROD1 subtypes, and miR‐9‐5p in the POU2F3 subtype. Comprehensive enhancer profiling using SCLC cell lines indicated that miR‐375 and miR‐9‐5p were regulated by super‐enhancers in a subtype‐specific manner. Multiplex immunohistochemistry by imaging mass cytometry found that the miR‐9‐5p‐high SCLC was characterized by a higher stromal area ratio, increased numbers of CD8+ T cells and CD163− macrophages in the intra‐tumoral area, and an increased number of plasma cells in the stromal area, as compared with the miR‐9‐5p‐low SCLC. Finally, clinicopathological analysis revealed that the miR‐375‐high SCLC was associated with YAP1 downregulation, increased serum pro‐gastrin‐releasing peptide levels, and poor prognosis. These findings highlight the critical role of super‐enhancer‐related miRNAs in the diversity of SCLC, and underscore the potential for novel diagnostic and prognostic biomarkers based on these subtype‐specific miRNAs. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 22 August 2025
- Published by Wiley in The Journal of Pathology
- Vol. 267 (2) , 168-180
Open AccessCharacteristic miRNA profiles represent clinicopathological diversity of small cell lung cancer
Small cell lung cancer (SCLC) is classified into distinct molecular subtypes based on the expression patterns of four transcription regulators: achaete–scute homolog 1 (ASCL1), neuronal differentiation 1 (NEUROD1), POU class 2 homeobox 3 (POU2F3), and yes‐associated protein 1 (YAP1). MicroRNAs (miRNAs) play critical roles in cancer cellular processes but their subtype‐specific implications in SCLC remain underexplored. Out of 46 surgically resected SCLC samples, miRNA visualization through in situ hybridization identified high expression of miR‐375 in the ASCL1, NEUROD1, and ASCL1/NEUROD1 subtypes, and miR‐9‐5p in the POU2F3 subtype. Comprehensive enhancer profiling using SCLC cell lines indicated that miR‐375 and miR‐9‐5p were regulated by super‐enhancers in a subtype‐specific manner. Multiplex immunohistochemistry by imaging mass cytometry found that the miR‐9‐5p‐high SCLC was characterized by a higher stromal area ratio, increased numbers of CD8+ T cells and CD163− macrophages in the intra‐tumoral area, and an increased number of plasma cells in the stromal area, as compared with the miR‐9‐5p‐low SCLC. Finally, clinicopathological analysis revealed that the miR‐375‐high SCLC was associated with YAP1 downregulation, increased serum pro‐gastrin‐releasing peptide levels, and poor prognosis. These findings highlight the critical role of super‐enhancer‐related miRNAs in the diversity of SCLC, and underscore the potential for novel diagnostic and prognostic biomarkers based on these subtype‐specific miRNAs. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 2 June 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (4) , 693-698
Mechanisms of resistance to antibody–drug conjugates in cancers
- 2 June 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (4) , 693-698
Mechanisms of resistance to antibody–drug conjugates in cancers
- Open Access
- 4 February 2025
- Published by Elsevier in Lung Cancer
- Vol. 201, 108422
Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study
- 4 February 2025
- Published by Elsevier in Lung Cancer
- Vol. 201, 108422
Open AccessFive-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study
- Open Access
- 7 February 2024
- Published by Wiley in Thoracic Cancer
- Vol. 15 (8) , 661-666
Genomic evolutional analysis of surgical resected specimen to assess osimertinib as a first‐line therapy in two patients with lung cancer harboring EGFR mutation: Case series
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is crucial for patients with lung cancer harboring EGFR mutations. However, almost all patients experience disease progression, regardless of their response to the targeted therapy, necessitating the development of additional treatment options. Two patients with lung cancer harboring EGFR‐L858R mutations in exon 21 were treated by surgical resection during successful osimertinib treatment. Because the pathological diagnosis was suspected to be pleural metastasis, osimertinib treatment was continued until disease progression. We analyzed the evolution of genomic alterations and the levels of AXL using tumor specimens obtained by repeated biopsies during the course of treatment: initial diagnosis, operation, and disease progression. Genetic alterations detected at the three time points were dramatically changed and showed reductions in numbers, while EGFR‐L858R mutations were detected in all samples tested in both patients. Immunohistochemical expression of AXL remained positive from the beginning of analysis to disease progression. Clonal evolution under oncogenesis is related to gradual accumulation of genomic alterations during tumor growth. However, our case series revealed that volume reduction procedures may cause this phenomenon. Therefore, identification of intrinsic drug‐resistant cells in tumors may be as important as detection of acquired genetic alterations.
- 7 February 2024
- Published by Wiley in Thoracic Cancer
- Vol. 15 (8) , 661-666
Open AccessGenomic evolutional analysis of surgical resected specimen to assess osimertinib as a first‐line therapy in two patients with lung cancer harboring EGFR mutation: Case series
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is crucial for patients with lung cancer harboring EGFR mutations. However, almost all patients experience disease progression, regardless of their response to the targeted therapy, necessitating the development of additional treatment options. Two patients with lung cancer harboring EGFR‐L858R mutations in exon 21 were treated by surgical resection during successful osimertinib treatment. Because the pathological diagnosis was suspected to be pleural metastasis, osimertinib treatment was continued until disease progression. We analyzed the evolution of genomic alterations and the levels of AXL using tumor specimens obtained by repeated biopsies during the course of treatment: initial diagnosis, operation, and disease progression. Genetic alterations detected at the three time points were dramatically changed and showed reductions in numbers, while EGFR‐L858R mutations were detected in all samples tested in both patients. Immunohistochemical expression of AXL remained positive from the beginning of analysis to disease progression. Clonal evolution under oncogenesis is related to gradual accumulation of genomic alterations during tumor growth. However, our case series revealed that volume reduction procedures may cause this phenomenon. Therefore, identification of intrinsic drug‐resistant cells in tumors may be as important as detection of acquired genetic alterations.
- 1 May 2022
- Published by Elsevier in Clinical Lung Cancer
- Vol. 23 (6) , 467-476
Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings
- 1 May 2022
- Published by Elsevier in Clinical Lung Cancer
- Vol. 23 (6) , 467-476
Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings
- Open Access
- 1 January 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 102, 529-531
Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation
- 1 January 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 102, 529-531
Open AccessPotential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation